Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe
- PDF / 243,145 Bytes
- 4 Pages / 595.276 x 793.701 pts Page_size
- 111 Downloads / 215 Views
giotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension 1,2
3
1
1,2
2,4
1
Xiao Meng , Ya Liu , Chenchen Wei , Kai Zhang , Yi Zhang , Ming Zhong , 1* 1* Cheng Zhang & Yun Zhang 1
The Key Laboratory of Cardiovascular Remodeling and Function Research, Ministry of Education of China, Chinese National Health
Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, China; 2 Department of Infectious Disease, Renmin Hospital of Wuhan University, Wuhan 430060, China; 3 Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China; 4 Department of Respiratory Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, China Received July 19, 2020; accepted September 1, 2020; published online September 21, 2020
Citation:
Meng, X., Liu, Y., Wei, C., Zhang, K., Zhang, Y., Zhong, M., Zhang, C., and Zhang, Y. (2020). Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension. Sci China Life Sci 63, https://doi.org/ 10.1007/s11427-020-1813-0
Dear Editor, Hypertension was reportedly the most common coexisting condition of COVID-19 as 15%–31.2% patients with COVID-19 had hypertension, and the incidence of hypertension reached 58.3% in COVID-19 patients requiring ICU care (Wang et al., 2020). However, it remains unclear whether combined hypertension carries an increased risk for a worse outcome in patients with COVID-19 and what clinical factors independently predict death in these patients. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are commonly used antihypertensive medications, but it is highly controversial whether ACEI/ARB treatment should be applied to patients with COVID-19 and hypertension because of a theoretical concern that these drugs may increase the expression of angiotensin converting enzyme 2 (ACE2), a high-affinity receptor of 2019-nCoV, thereby facilitating invasion of 2019-nCoV into the human body (Zhou et al., 2020). *Corresponding authors (Yun Zhang, email: [email protected]; Cheng Zhang, email: [email protected])
To address these questions, a total of 580 patients admitted into Renmin Hospital of Wuhan University for COVID-19 from January 12, 2020 to March 27, 2020 were enrolled. Patients were divided into two groups according to their history of hypertension: hypertension (HT) group (blood pressure ≥140/90 mmHg) and normotension (NT) group (blood pressure
Data Loading...
